The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017
The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017
Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study Source: ERJ Open Res, 7 (1) 00778-2020; 10.1183/23120541.00778-2020 Year: 2021
Adverse effects of MDR-TB treatment with a standardized regimen: A report from Iran Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Management of adverse drug events in TB therapy Source: Eur Respir Mon 2012; 58: 167-193 Year: 2012
The incidence of adverse reactions in anti-tuberculosis chemotherapy in S-W Romania Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011
Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study Source: Eur Respir J 2001; 18: 369-375 Year: 2001
Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen Source: Annual Congress 2012 - Tuberculosis: clinical findings I Year: 2012
Adverse drug reactions to second line anti tuberculosis drugs: A prospective study in Mumbai, India Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
The patterns of inadequate drug administration in children with asthma: a multi-center retrospective study Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002
Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009
Efficacy of isoniazid preventive therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders-a retrospective cohort study in Taiwan Source: International Congress 2017 – Migrants and screening Year: 2017
A clinical and outcomes assessment of the management of community-acquired pneumonia (CAP): a multinational, prospective, double-blind comparison of moxifloxacin to standard first-line oral monotherapy or combination regimen Source: Eur Respir J 2001; 18: Suppl. 33, 189s Year: 2001
Frequency of adverse reactions to first-line anti-tuberculosis chemotherapy in patients with relapse(RTB)and newly diagnosed tuberculosis(NDTB) Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018
Impact of adverse drug reactions on treatment interruption in TB patients with and without HIV coinfection Source: ISSN=ISSN 1810-6838, ISBN=, page=190 Year: 2006
The effectiveness and safety of empirical anti-TB therapy in a population with high TB prevalence Source: Eur Respir J 2001; 18: Suppl. 33, 468s Year: 2001
Tuberculosis in HIV-infected persons in the context of wide availability of highly active antiretroviral therapy Source: Eur Respir J 2004; 24: 11-17 Year: 2004
Metformin use and post-exposure incident tuberculosis: a nationwide tuberculosis-contact cohort study in Taiwan Source: ERJ Open Res, 6 (3) 00050-2020; 10.1183/23120541.00050-2020 Year: 2020
Paradoxical reactions during treatment of tuberculosis: A prospective study Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities Year: 2010
Benefits of interferon-αcon-1 (IFN-αcon-1) as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy. Results of a 12-month prospective case-controlled study Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006